Sugi Predict

Sugi Predict / Compounds / SCHEMBL19458908

SCHEMBL19458908

SCHEMBL19458908

CC(C)(C)OC(=O)N1CCN(c2ccc(B3OC(C)(C)C(C)(C)O3)c(OC(F)F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 7/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ PDK2 Q15119 1/20 0.46
▸ PDE4D Q08499 2/20 0.41
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383479 0.88 MAPT (0.49) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL31342252 0.87 PDK2 (0.48) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL2387434 0.85 MAPT (0.50) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL29373645 0.85 MAPT (0.50) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL18621690 0.84 MAPT (0.51) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL12331687 0.84 MAPT (0.51) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL18376323 0.83 PDK2 (0.50) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL20523595 0.82 MAPT (0.49) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL31111655 0.82 PDK2 (0.48) ALKMAPTALDH1A1LMNAPDK2
SCHEMBL2724586 0.81 MAPT (0.53) ALKMAPTALDH1A1LMNAPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-12595265-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2026-04-07 — — US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2024-05-16 — — US disclosed
EP-4285996-A2 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2023-12-06 — — EP disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 — — US disclosed
US-20220315585-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2022-10-06 — — US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 — — US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 — — US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 — — US disclosed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 — — EP disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 ALK 4/4885MAPT 3886/4885ALDH1A1 3277/4885
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ALK 4/4885MAPT 3886/4885ALDH1A1 3277/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 ALK 53/4885MAPT 4555/4885ALDH1A1 2085/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ALK 4/4885MAPT 3886/4885ALDH1A1 3277/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 ALK 4/4885MAPT 3886/4885ALDH1A1 3277/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 ALK 6/4885MAPT 3683/4885ALDH1A1 2488/4885
US-12595265-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVRL1, ACVR2A ALK 7/4885MAPT 4748/4885ALDH1A1 2050/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ALK 4/4885MAPT 3886/4885ALDH1A1 3277/4885
US-20220315585-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ALK 4/4885MAPT 3886/4885ALDH1A1 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.